A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on ...
New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib ...
Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) with the addition of pemetrexed and platinum-based ...
New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy ...
FLAURA2 phase III trial of AstraZeneca’s Tagrisso plus chemotherapy demonstrated a median overall survival in EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, September ...
Lymphedema After Breast Cancer: Incidence, Risk Factors, and Effect on Upper Body Function In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more ...
Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination Overall survival results reinforce TAGRISSO as the backbone therapy in EGFRm lung ...
Clinical Trials Arena on MSN
AstraZeneca’s Tagrisso combination shows survival benefit in lung cancer trial
A straZeneca's Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy, has shown a ...
Results from the Phase III FLAUR2 trial (NCT04035486) showed that Tagrisso combined with pemetrexed and platinum-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback